- Home
- DSP vs SCPH Comparison
DSP vs SCPH Comparison
Compare DSP & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- SCPH
- Stock Information
- Founded
- DSP 1999
- SCPH 2013
- Country
- DSP United States
- SCPH United States
- Employees
- DSP N/A
- SCPH N/A
- Industry
- DSP EDP Services
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- SCPH Health Care
- Exchange
- DSP Nasdaq
- SCPH Nasdaq
- Market Cap
- DSP 167.4M
- SCPH 163.3M
- IPO Year
- DSP 2021
- SCPH 2017
- Fundamental
- Price
- DSP $9.93
- SCPH $5.05
- Analyst Decision
- DSP Strong Buy
- SCPH Strong Buy
- Analyst Count
- DSP 5
- SCPH 2
- Target Price
- DSP $11.60
- SCPH $19.00
- AVG Volume (30 Days)
- DSP 98.0K
- SCPH 378.8K
- Earning Date
- DSP 08-12-2024
- SCPH 08-14-2024
- Dividend Yield
- DSP N/A
- SCPH N/A
- EPS Growth
- DSP N/A
- SCPH N/A
- EPS
- DSP N/A
- SCPH N/A
- Revenue
- DSP $243,250,000.00
- SCPH $24,048,000.00
- Revenue This Year
- DSP $19.71
- SCPH $195.62
- Revenue Next Year
- DSP $12.84
- SCPH $145.07
- P/E Ratio
- DSP N/A
- SCPH N/A
- Revenue Growth
- DSP 20.25
- SCPH 549.77
- 52 Week Low
- DSP $4.98
- SCPH $3.24
- 52 Week High
- DSP $12.36
- SCPH $7.71
- Technical
- Relative Strength Index (RSI)
- DSP 40.21
- SCPH 52.33
- Support Level
- DSP $10.27
- SCPH $4.86
- Resistance Level
- DSP $11.41
- SCPH $5.30
- Average True Range (ATR)
- DSP 0.40
- SCPH 0.30
- MACD
- DSP -0.08
- SCPH -0.02
- Stochastic Oscillator
- DSP 1.33
- SCPH 30.66
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.